Get the Stockscreener App
4.87
1.30%
0.02
After Hours:
4.87
Voyager Therapeutics Inc stock is traded at $4.87, with a volume of 1.30M.
It is up +1.30% in the last 24 hours and up +43.65% over the past month.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
See More
Previous Close:
$4.85
Open:
$4.89
24h Volume:
1.30M
Relative Volume:
2.04
Market Cap:
$270.77M
Revenue:
$40.37M
Net Income/Loss:
$-119.72M
P/E Ratio:
-2.387
EPS:
-2.0402
Net Cash Flow:
$-135.06M
1W Performance:
+25.01%
1M Performance:
+43.65%
6M Performance:
+17.53%
1Y Performance:
+21.01%
1-Day Range:
$4.79
$5.025
1-Week Range:
$3.765
$5.478
52-Week Range:
$2.645
$5.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Name
Voyager Therapeutics Inc
Sector
Industry
Phone
857-259-5340
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
4.87 | 269.66M | 40.37M | -119.72M | -135.06M | -2.0402 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.00 | 125.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.65 | 81.90B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
708.84 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.23 | 42.50B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
285.30 | 33.16B | 5.36B | 287.73M | 924.18M | 2.5229 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-02-24 | Initiated | Citigroup | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Oct-16-24 | Initiated | Leerink Partners | Outperform |
| Mar-26-24 | Initiated | Guggenheim | Buy |
| Mar-19-24 | Initiated | H.C. Wainwright | Buy |
| Mar-07-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-10-23 | Initiated | Truist | Buy |
| Mar-10-23 | Initiated | Oppenheimer | Outperform |
| Oct-07-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-03-21 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-03-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-24-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-23-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-10-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-19-20 | Initiated | The Benchmark Company | Buy |
| Feb-06-20 | Initiated | Oppenheimer | Outperform |
| Nov-15-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Sep-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-18 | Initiated | H.C. Wainwright | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-12-18 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-02-18 | Initiated | Morgan Stanley | Overweight |
| Nov-28-17 | Resumed | Piper Jaffray | Overweight |
| Oct-31-17 | Initiated | Robert W. Baird | Outperform |
| Oct-27-17 | Initiated | Canaccord Genuity | Buy |
| Oct-23-17 | Reiterated | Stifel | Buy |
| Oct-12-17 | Initiated | Raymond James | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-28-17 | Resumed | Stifel | Buy |
View All
Voyager Therapeutics Inc Stock (VYGR) Latest News
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Voyager Therapeutics Faces Rising Tariff and U.S.–China Geopolitical Risks as BIOSECURE Act Threatens Key Chinese CDMO Partnerships - TipRanks
Voyager Therapeutics (VYGR) Q4 Loss Of US$27 Million Reinforces Bearish Profitability Concerns - simplywall.st
Voyager Therapeutics, Inc. 2025 Annual Report: Key Risks, Forward-Looking Statements, and Business Overview - Minichart
Voyager Therapeutics Inc earnings beat by $0.05, revenue topped estimates - Investing.com UK
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Voyager Therapeutics Q4 2025 Financial Report: Revenue Surpasses EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Voyager (VYGR) Surpasses Q4 Revenue Expectations, Sets Strategic Vision for 2026 - GuruFocus
Voyager Therapeutics: Fourth Quarter Earnings Overview - Bitget
Gene therapy pioneer Voyager Therapeutics Inc (stock code: VYGR) announced that by the end of fiscal year 2025, the company held strong cash and cash equivalents totaling $202 million. - Bitget
Voyager Therapeutics (NASDAQ:VYGR) Announces Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Voyager Therapeutics: Q4 Earnings Snapshot - 10TV
Voyager Therapeutics reports Q4 2025: $15.3M Q4 collaboration revenue, $119.7M full-year net loss - TradingView
Voyager Therapeutics 2025 10-K: Collaboration revenue $40.4M, Net loss $(119.7)M - TradingView
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - GlobeNewswire
Is Voyager Therapeutics Inc. stock trading at a premium valuation2026 Summary & Expert-Curated Trade Recommendations - Naître et grandir
Will Voyager Therapeutics Inc. stock gain from lower inflationEarnings Growth Report & Fast Entry Momentum Alerts - mfd.ru
Voyager Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Tuesday - MarketBeat
Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028 - Defense World
Voyager Therapeutics at Oppenheimer Conference: Strategic Insights on Alzheimer’s By Investing.com - Investing.com Canada
Todd Alfred Carter Sells 4,174 Shares of Voyager Therapeutics (NASDAQ:VYGR) Stock - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) CFO Sells $17,598.36 in Stock - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) CEO Alfred Sandrock Sells 14,197 Shares - MarketBeat
Robin Swartz, Voyager Therapeutics COO, sells $24k in VYGR stock - Investing.com Canada
Alfred Sandrock, Voyager Therapeutics CEO, sells $53806 in stock By Investing.com - Investing.com Canada
Voyager Therapeutics CFO sells $17,598 in stock By Investing.com - Investing.com Canada
VYGR | Voyager Therapeutics, Inc. Common FinancialsIncome Statement - Quiver Quantitative
Voyager Therapeutics (VYGR) CFO executes 4,668-share tax sell-to-cover trade - Stock Titan
Voyager Therapeutics (VYGR) CSO auto-sells shares for tax bill - Stock Titan
Earnings Miss: How does Voyager Therapeutics Inc compare to its peersGlobal Markets & Accurate Buy Signal Notifications - baoquankhu1.vn
ARMISTICE CAPITAL, LLC Reduces Stake in Voyager Therapeutics Inc. - GuruFocus
4,174-Share Rule 144 Notice for Voyager Therapeutics (NASDAQ: VYGR) - Stock Titan
VYGR (NASDAQ: VYGR) Rule 144 notice: 6,458 shares tied to vesting - Stock Titan
14,197 shares vest; director sold 12,192 and 11,732 (VYGR) - Stock Titan
VYGR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Voyager Therapeutics (NASDAQ:VYGR) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
[Form 4] Voyager Therapeutics, Inc. Insider Trading Activity - Stock Titan
Is Voyager Therapeutics Inc. stock a smart retirement pickEarnings Overview Report & Daily Market Momentum Tracking - mfd.ru
Tax-driven sale: Voyager (NASDAQ: VYGR) CSO sells 3,301 shares - Stock Titan
Voyager Therapeutics (VYGR) Form 144: 3,301-share proposed sale; insider sold 3,525 - Stock Titan
EcoR1 discloses 6.8% Voyager Therapeutics (VYGR) ownership stake - Stock Titan
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-02-14 07:15:36 - mfd.ru
Voyager Therapeutics Announces Chief Medical Officer Resignation - The Globe and Mail
What analyst consensus says on Voyager Therapeutics Inc. stockDividend Hike & Target Return Focused Picks - mfd.ru
Is Voyager Therapeutics Inc. subject to activist investor interestWeekly Investment Summary & Daily Chart Pattern Signals - mfd.ru
Todd Alfred Carter Sells 3,525 Shares of Voyager Therapeutics (NASDAQ:VYGR) Stock - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) COO Sells $17,590.65 in Stock - MarketBeat
Earnings Miss: Can Voyager Therapeutics Inc reach all time highs this year2025 Growth vs Value & AI Powered Market Entry Ideas - baoquankhu1.vn
Alfred Sandrock Sells 12,192 Shares of Voyager Therapeutics (NASDAQ:VYGR) Stock - MarketBeat
Voyager Therapeutics Inc Stock (VYGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Voyager Therapeutics Inc Stock (VYGR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sandrock Alfred | President and CEO |
Feb 24 '26 |
Sale |
3.79 |
14,197 |
53,807 |
484,060 |
| Jorgensen Nathan D. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.77 |
4,668 |
17,598 |
151,416 |
| Carter Todd Alfred | Chief Scientific Officer |
Feb 24 '26 |
Sale |
3.76 |
4,174 |
15,694 |
145,718 |
1.42%
0.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):